Synopsis: Fermenta Biotech Limited has received FSSAI approval for its plant-based Vitamin D3 (VITADEE Green®) for use in health supplements, nutraceuticals, and food products. The approval expands the company’s addressable market in India while strengthening its position in sustainable nutrition solutions.
Shares of Fermenta Biotech Limited are likely to remain in focus after the company announced that its plant-based Vitamin D3 (Cholecalciferol), marketed as VITADEE Green®, has received approval from the Food Safety and Standards Authority of India (FSSAI) for use as an ingredient in health supplements, nutraceuticals, and food products.
Fermenta Biotech Limited has a total market capitalization of approximately Rs. 1,143.98 crore. The company’s shares were trading at Rs. 388.70 apiece on the stock exchange, up by 13.32 percent. The stock has gained 7.67 percent over the last five trading sessions, while it has gained 13.04 percent over the last month. The stock touched a 52-week high of Rs. 401 and a 52-week low of Rs. 249.
According to the company’s press release, the regulatory approval allows Indian manufacturers to incorporate VITADEE Green® into fortified foods, beverages, dietary supplements, and nutraceutical products. The company stated that the product is backed by an Indian process patent and offers a sustainable, scalable, and plant-derived source of Vitamin D3, supporting the growing demand for vegetarian nutrition products in the country.
The approval significantly expands Fermenta’s addressable market by enabling direct participation in India’s rapidly growing nutraceutical and food fortification segments. Unlike conventional Vitamin D3, which is largely derived from animal sources, VITADEE Green® provides a plant-based alternative, making it particularly attractive for vegetarian consumers and manufacturers looking to offer clean-label and plant-based nutrition products.
India continues to face widespread Vitamin D deficiency despite abundant sunlight, driven by changing lifestyles, urbanization, and limited sun exposure. This has led to increasing demand for fortified foods and dietary supplements. At the same time, rising health awareness, preventive healthcare trends, and increasing disposable incomes are accelerating growth in the nutraceutical industry, creating significant opportunities for manufacturers of specialty nutritional ingredients.
The approval also aligns with the government’s emphasis on Make in India and food fortification initiatives. By manufacturing the product domestically, Fermenta aims to reduce dependence on imports while providing Indian formulators with access to a locally produced, science-backed Vitamin D3 ingredient. The company believes this could support broader efforts to address nutritional deficiencies across the country.
For investors, the FSSAI approval represents a strategic milestone rather than an immediate financial trigger. It opens new commercialization opportunities in India’s fast-growing nutrition and wellness market, strengthens Fermenta’s differentiated product portfolio, and could support long-term revenue growth through increased adoption by food, beverage, and nutraceutical manufacturers.
Incorporated in 1951, Fermenta Biotech Limited manufactures active pharmaceutical ingredients (APIs), Aqua CHL, biotechnology products, and nutraceutical ingredients. The company serves customers across pharmaceuticals, dietary supplements, food and beverages, veterinary healthcare, and animal nutrition through a diversified portfolio of science-based nutritional and specialty products.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses arising from decisions based on this article. Please consult your investment advisor before investing.
